A whopping 39% of venture groups say they have pulled back on their investments in the U.S. life sciences field over the past three years. And the same proportion say they'll continue to hold back over the next few years, according to a new survey out from the National Venture Capital Association. If that proves to be the case, adds the venture group, the shortfall could starve the industry of $500 million.
To read the full, original article click on this link: VCs blame FDA for bleak investment outlook for drugs and devices - FierceBiotech
Author:John Carroll
